2019年3月19日
Various generics manufacturers have won in the second instance in the dispute over supplementary protection certificates for cholesterol-lowering drug Inegy. The Higher Regional Court Düsseldorf dismissed the appeal of US originator Merck Sharp Dome (MSD) (case IDs: I-2 U 58/18 - I-2 U 64/18 and I-2 U 82/18). The various pharmaceutical companies may continue to market imitation products in Germany, using the active substance combination ezitimibe and simvastatin.
Read the whole article Generics manufacturers prevail over Hogan Lovells client MSD.
We explain the 5 biggest pitfalls
作者 Dr. Anja Lunze, LL.M. 以及 Dr. Nora E. Wessendorf, LL.M. (Washington)